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Abstract
Chronic or recurrent musculoskeletal pain is a common complaint in children. Among the most common causes
for this problem are different conditions associated with hypermobility. Pediatricians and allied professionals should
be well aware of the characteristics of the different syndromes associated with hypermobility and facilitate early
recognition and appropriate management. In this review we provide information on Benign Joint Hypermobility
Syndrome, Ehlers-Danlos Syndrome, Marfan Syndrome, Loeys-Dietz syndrome and Stickler syndrome, and discuss
their characteristics and clinical management.
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Introduction
Chronic or recurrent musculoskeletal pain is a common
complaint in children, affecting between 10 % and 20 %
of children. It is one of the more frequent reasons for
seeking a primary care physician’s evaluation and pos-
sible rheumatology referral [1, 2]. A wide variety of
non-inflammatory conditions may cause musculoskel-
etal pain in the pediatric age, and the most common
causes seen by paediatric rheumatologists include
conditions associated with hypermobility. Hypermobil-
ity may have a significant impact on quality of life of
affected children and their parents, even in the milder
forms [3]. All physicians and allied professionals that
may be involved in the care of children with musculoskel-
etal complaints should therefore be well trained to
recognize hypermobility and to run the differential diag-
nosis between the various clinical entities associated with
it. A critical approach to a child with hypermobility is cru-
cial to correctly identify the underlying cause and avoid
time/money- consuming investigations.
In this paper we review different etiologies of muscu-
loskeletal pain associated with hypermobility, including
some genetic disorders, and discuss the clinical approach
in these children.
Review
Benign joint hypermobility syndrome (BJHS)
Children with hypermobile joints by definition display a
range of movement that is considered excessive, taking
into consideration the age, gender and ethnic background
of the individual. It is estimated that at least 10–15 % of
normal children have hypermobile joints and the term
joint hypermobility syndrome (JHS) is reserved to the
cases of joint hypermobility associated with symptoms
with no other causes found for them [4–6]. JHS can be as-
sociated with hereditary connective tissue disorders, and
the term “Benign” is used in contrast to more serious and
potentially complicated or life-threatening musculoskeletal
syndromes such as some forms of Ehlers-Danlos syn-
drome (EDS), Marfan syndrome, and Loeys-Dietz
syndrome. The prevalence of JHS is not known with
precision, given the lack of studies of large cohorts.
Sperotto et al., conducted a cross sectional study in a co-
hort of healthy schoolchildren, aged 8–13 years from the
province of Padua, Italy, and found that BJHS occurred in
the 13,2 % of the 289 children evaluated [7].
Even if BJHS is very common, this condition is largely
under-recognized by primary care physicians and often
poorly managed. Symptoms frequently start in childhood
and continue into adult life. The pathophysiology of be-
nign joint hypermobility is unclear. Hypermobility is
more common in childhood and adolescence, in females,
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and in some ethnicities, and it tends to lessen during
adulthood. Still, polyarticular hypermobility may be
present in up to 30 % of males and 40 % of females
during early adulthood [8]. For the majority of individ-
uals joint hypermobility may be of no consequence,
and what brings a proportion of subjects to develop
BJHS is not fully understood. BJHS seems to be trans-
mitted by an autosomal pattern, and first-degree rela-
tives with the disorders can be identified in many
cases. Variable penetrance is generally observed [9].
With the exception of a minority of patients, who
show a deficiency of tenascin X, no abnormality in col-
lagen or related proteins has been identified as a cause
for BJHS [10]. Joint pain is thought to be caused by ex-
cessive movement, increasing stress on joint surfaces,
ligaments and adjacent structures. Other factors may
contribute to the development of the syndrome, such
as poor proprioception, autonomic dysfunctions and
fatigue secondary to poor sleep [11].
The predominant presenting complaint is pain, which
may be widespread and debilitating. The pain typically
starts during or after activity. The most common
affected sites are the lower limbs after walking (for ex-
ample walking to and from school). Children usually re-
port excess fatigue, handwriting difficulties or ‘clicking
or cracking’ joints. Occasionally episodes of joint swell-
ing lasting hours to days, joint dislocations, or more
commonly subluxations with spontaneous reduction
are reported. Back-pain is also a common complaint
because the lumbar spine is one of the most mobile
sections of the vertebral column and the excessive
movements may lead to pain in hypermobile subjects.
Heavy school bags are often an aggravating feature.
Chronic pain results in a reduced exercise tolerance
and can negatively impact patients’ life.
A significant proportion of subjects progressively quit
sports and other physical activities. In addition, pain
amplification is a common feature in these cases [12].
BJHS has been considered to cause only musculoskeletal
symptoms for many years, but there is now mounting
evidence that many other extra-skeletal manifestations
may occur. This symptoms arise usually after the third
decade of life, but have been described in adolescents,
and may be due to connective tissue abnormalities, link-
ing BJHS and other hereditary disorders of connective
tissues, namely Ehlers-Danlos syndrome type III. These
include functional and anatomic gastrointestinal tract
abnormalities (constipation, bloating, diarrhea, hiatal
hernias), autonomic dysfunctions (postural tachycardia
syndrome, palpitations, orthostatic intolerance, head-
ache, fatigue) and skin abnormalities (easy bruising,
striae) [13, 14]. Some of these symptoms are overlapping
with those observed in Juvenile Fibromyalgia (JFM), and
indeed there are few reports describing high incidence
of BJHS in children with JFM. Furthermore, children
who have both JFM and BJHS may exhibit lower tender-
points thresholds and a greater number of tender-points
compared to children with JFM but no benign joint hy-
permobility [15].
The “Beighton score” (derived from the original one
by Carter and Wilkinson) is commonly used to diagnose
hypermobility. Hypermobility is present if 4 out of 9
points are scored. When this score is applied to normal
children, a large proportion of the population is hyper-
mobile (Table 1, Figs. 1, 2 and 3). This reflects the fact
that, as already discussed, connective tissue structures
may be looser and joints hypermobile in childhood, es-
pecially compared to adults. For these reasons it may be
better to consider a Beighton score of 5 or more positive
[16]. The Beighton score has been incorporated into a
more comprehensive set of criteria called the Brighton
Criteria (Table 2), which take into account the possible
multisystemic nature of this condition. Although these
criteria have not been formally validated in a pediatric
population, they have been used in some studies on chil-
dren with hypermobility [17–19].
The management of individuals with BJHS can be very
challenging and there are no evidence-based manage-
ment strategies currently available. Acute pain episodes
are commonly managed using taping, bracing or splint-
ing or with non-steroidal anti-inflammatory drugs as
needed. However reassurance and a multi-disciplinary
training program are the mainstays of long term man-
agement. Physical therapy is of the outmost importance,
and encouraging an active lifestyle may improve function
and enhance quality of life [20]. As general principles,
strengthening exercises focused on muscles around
hypermobile joints may help to enhance joint support
throughout movement and reduce pain; closed chain ex-
ercises may enhance proprioceptive feedback and
optimize muscle action. Proprioception may be im-
proved also by coordination and balance exercises. Phys-
ical therapy should also encompass a generalized
exercise programme, addressing cardio-respiratory, mus-
culoskeletal and neurological aspects of movement with
the aim to reduce deconditioning [20]. As already
Table 1 Beighton scoring system for joint hypermobility
(adapted from Junge et al. [16])
Scoring 1 point each side
1. Passive dorsiflexion of the 5th metacarpophalangeal joint to >90°
2. Passive apposition of thumb to the flexor aspect of forearm
3. Hyperextension of the elbow >10°
4. Hyperextension of the knee >10°
Scoring 1 point
5. Flexion of the trunk with knees straight and both palms resting
easily on floor
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mentioned, the Health Related Quality of Life in chil-
dren with hypermobility and their parents may be worse
than that of healthy controls and this may well be sec-
ondary to the presence of chronic pain and fatigue, that
act as stressors in everyday life. This is an important as-
pect to consider for physicians approaching a child with
BJHS, that should not underestimate the burden of this
condition, often interpreted as benign and not worth
any intervention [3].
Ehlers-Danlos Syndromes (EDSs)
EDSs comprise a very heterogeneous group of heritable
disorders of connective tissue. The increased flexibility
and fragility of the soft connective tissues result in a
wide range of changes in the skin, ligaments, joints,
blood vessels and internal organs (Fig. 4). The current
Villefranche classification recognizes six subtypes, ac-
cording to clinical features, inheritance pattern and
underlying molecular defects (Table 3). This classifica-
tion underlines the extreme heterogeneity at both the
clinical and the molecular level [21]. In the last few
years, rarer phenotypes that do not fit in the Villefranche
classification have been described. The prevalence of
EDS is estimated to be approximately one in 5000 births,
with no racial predisposition [22].
The connective tissue fragility follows abnormalities in
the expression or structure of the fibrillar collagen types
I, III and V, as well as enzymatic abnormalities in the
post-translational modification and processing of these
collagens. Mutations in the COL5A1 and COL5A2
genes, encoding the α1- and the α2-chains of type V col-
lagen, respectively, are found in approximately 50 % of
individuals with the classic type of EDS. Mutations in
Fig. 1 Passive apposition of thumb to the flexor aspect of forearm
in a child with BJHS
Fig. 2 Hyperextension of the elbow in a child with BJHS
Fig. 3 Hyperextension of the knee in a child with BJHS
Table 2 The Brighton criteria for the diagnosis of BJHS (adapted
from Graham et al. [17]
Major criteria
1. A Beighton score of 4/9 or greater (either currently or historically)
2. Arthralgia for longer than 3 months in four or more joints.
Minor criteria.
1. A Beighton score of 1,2, or 3/9 (0,1,2,or 3 if aged 50+).
2. Arthralgia (for 3 months or longer) in one to 3 joints or back pain for
(for 3 months or longer), spondylosis, spondylolysis/spondylolisthesis.
3. Dislocation/subluxation in more than one joint, or in one joint on
more than one occasion.
4. Soft tissue rheumatism: three or more lesions (e.g., epicondylitis,
tenosynovitis, bursitis).
5. Marfanoid habitus (tall, slim, span/height ration >1.03 upper: lower
segment ration less than 0.89, arachnodactyly (positive steinberg/
wrist signs).
6. Abnormal skin striae, hyperextensibility, thin skin, papyraceous
scarring.
7. Eye signs: drooping eyelids or myopia or antimongoloid slant.
8. Varicose veins or hernia or uterine/rectal proplapse.
BJHS is diagnosed in the presence of two major criteria or one major
and two minor criteria, or four minor criteria. Two minor criteria will
suffice where there is an unequivocally affected first-degree relative.
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TNX-B, encoding for Tenascin X, in approximately 5 %
of patients with the hypermobility type, while vascular
EDS is caused by heterozygous mutations in the
COL3A1 gene, encoding type III collagen [23, 24].
The clinical spectrum of EDSs varies from mild skin
and joint hyperlaxity to severe physical disability and
life-threatening vascular complications. The classic, hy-
permobility and vascular subtype of EDS are the most
common, whereas the kyphoscoliosis, arthrochalasis and
dermatosparaxis types are very rare conditions. The
diagnosis of the autosomal dominant (AD) classic sub-
type of EDS requires the presence of skin hyper-
extensibility, widened atrophic scars and joint hypermo-
bility. These are the three major diagnostic criteria, next
to a series of ‘minor’ diagnostic manifestations. Charac-
teristic facial features include epicanthic folds, excess
skin over the eyelids, presence of dilated scars on the
forehead and vaulted palate. Joint hypermobility is usu-
ally generalized and can vary in severity and with age. At
birth, uni- or bilateral dislocation of the hip may be
present. Even if the hypermobility is asymptomatic, this
condition can result in childhood in congenital club foot,
pes planus and joint effusions. In young adulthood the
classic subtype can be complicated by repetitive subluxa-
tions and dislocations either spontaneously or after min-
imal trauma. Patients usually report chronic and recurrent
pain that is difficult to treat and premature osteoarthritis
is a major concern. One of the most typical features is the
skin hyper-extensibility, which means that the skin
stretches easily but snaps back after release. The skin is
often smooth and velvety to the touch [23] (Fig. 4).
For pediatric rheumatologists, a real diagnostic chal-
lenge is represented by the hypermobility subtype of EDS
(EDS-HT), which is by far the most common subtype.
The genetic basis of EDS-Hybermobile is largely unknown
and a reliable diagnostic test for this EDS subtype is
lacking [25]. According to the Villefranche classification,
the major diagnostic criteria are generalized joint hyper-
mobility and presence of typical skin manifestations. How-
ever, these features are usually more subtle than in the
classic type of EDS but these criteria are nevertheless
helpful to differentiate this form of EDS from the more
common “Benign joint hypermobility syndrome (BJHS)”
[26]. It is still a matter of debate if EDS-HT and BJHS
really represents two different diseases or if they should be
reviewed as a spectrum of a single entity, sharing common
genetic bases and showing considerable variability in clin-
ical presentation, between as well as within families.
Joint hypermobility is typically limited to the small joints
of the hands in the vascular subtype. This subtype has the
worst prognosis because of a high rate of spontaneous ar-
terial rupture usually in the third or the fourth decade of
life. Unlike other EDS types, the skin is not hyper-
extensible, but rather thin and translucent, showing a
visible venous pattern over the chest, abdomen and ex-
tremities. Excessive bruising is the most common sign and
is often the presenting complaint, especially in children.
Other early manifestations include premature rupture of
the membranes, congenital clubfoot or congenital hip dis-
location, inguinal hernia, and severe varicosities. The facial
and cutaneous features may be very subtle or even absent
[27]. If there is a strong clinical suspicion of vascular EDS,
direct DNA analysis is mandatory, even in the absence of
an abnormal biochemical abnormality.
The management of children with Ehlers-Danlos syn-
dromes requires a multidisciplinary approach. Children
with pronounced skin fragility should be advised to
avoid contact sports and to wear protective pads or ban-
dages in order to prevent bruises and hematomas. Cuta-
neous stitches should be left in place twice as long as
usual, and additional fixation of adjacent skin with adhe-
sive tape can help to prevent stretching of the scar. In
children physio-therapeutic support is important. Acet-
aminophen should be preferred over NSAIDs for joint
pain and thus minimizing the risk of easy bruising due
to platelet disfunction. For the same reason COX-2 in-
hibitors may be an option, although no studies have
been published on their use in EDS. Patients with mitral
valve prolapse and regurgitation require antibiotic
prophylaxis for bacterial endocarditis. A baseline echo-
cardiogram with aortic diameters measurement is rec-
ommended before 10 years of age, with follow-up
studies timed according to whether an abnormal meas-
urement is found. A useful resource for these measure-
ments is parameterz.blogspot.in. For the vascular and
vascular-like types of EDS, some prophylactic measures
are of particular importance. Invasive vascular proce-
dures such as arteriography and catheterization should
also be avoided because of the risk for life-threatening
vascular rupture. Surgical interventions are generally
Fig. 4 Skin hyper extensibility in a child with EDS
subtype hypermobile
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discouraged because of increased vascular fragility, and
conservative therapy is recommended [28, 29].
Marfan Syndrome (MS)
MS is an hereditary autosomal dominant, multisystem
disorder of connective tissue with extensive clinical
variability. It is a relatively common condition, with
approximately 1 in 5000 people affected. This disease
demonstrates autosomal-dominant inheritance with
high penetrance and marked inter- and intra-familial
variability [30]. It is caused by defects in FBN1, the
gene that codes for the protein fibrillin, although pa-
tients with mutations in other genes, including
TGFBR1 and TGFBR2, have also been rarely reported
[31]. Mutations in FBN1 are associated with a wide
phenotypic spectrum ranging from classic features of
Table 3 Ehlers-Danlos Syndromes classification (adapted from Beighton P et al. [21])
Type Clinical manifestations IPa Protein Gene
Major criteria Minor criteria
Classic (type I/II) Skin hyperextensibility Easy bruising AD Type V procollagen
(~50 %)
COL5A1
Widened atrophic scarring Molluscoid pseudotumors COL5A2
Joint hypermobility Subcutaneous spheroids
Smooth and velvety skin Muscular hypotonia
Complications of joint hypermobility
Surgical complications
Positive family history
Hypermobility
(type III)
Generalized joint hypermobility
mild skin involvement
Recurring joint dislocations AD Tenascin X (~5 %) TNX-B
Chronic joint pain
Positive family history
Vascular (type IV) Excessive bruising Acrogeria AD Type III procollagen COL3A1
Thin, translucent skin Early-onset varicose veins
Arterial/intestinal/uterine fragility
or rupture
Hypermobility of small joints
Characteristic facial appearance Tendon and muscle rupture
Arteriovenous or carotid-cavernous
sinus fistula
Pneumo (hemo)thorax
Positive family history, sudden
death in close relative(s)
Kyphoscoliotic
(type VI)
Severe muscular hypotonia at birth Tissue fragility, including atrophic scars AR Type VIA: Lysyl hydroxylase 1 LH-1 (PLOD1)
Generalized joint laxity Easy bruising
Kyphoscoliosis at birth Arterial rupture
Scleral fragility and rupture of the globe Marfanoid habitus Type VIB: not known
Microcornea
Osteopenia
Arthrochalasis
(type VII A & B)
Severe generalized joint hypermobility
with recurrent subluxations
Skin hyperextensibility AD Type I procollagen COL1A1
Congenital bilateral hip dislocation Tissue fragility, including atrophic scars COL1A2
Easy bruising
Muscular hypotonia
Kyphoscoliois
Mild osteopenia
Dermatosparaxis
(type VII C)
Severe skin fragility Soft, doughy skin texture Procollagen-N-proteinase ADAMTS-2
Sagging, redundant skin Premature rupture of membranes
Excessive bruising Large herniae
aIP inheritance pattern
AD Autosomal Dominant, AR Autosomal Recessive
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Marfan syndrome presenting in childhood and early
adulthood to severe neonatal presentation [32]. Ad-
vanced paternal age is a risk factor.
Cardinal features involve the ocular, musculoskeletal,
and cardiovascular systems. Skeletal system involvement
in Marfan syndrome is characterized by bony over-
growth; such overgrowth may be noticeable at birth or
can develop in young children and results in dispropor-
tional long limbs. Frequent findings are pectus excava-
tum, pectus carinatum, scoliosis or spondylolisthesis,
calcaneal displacement, “protrusio acetabuli”, arachno-
dactyly, and pes planus. Recently, Marfan patients have
been reported to have reduced bone mass and muscle
mass, compared to healthy controls. All this skeletal ab-
normalities may account for the very high incidence of
severe daily pain that Marfan patients report [33].
Joint laxity may be significant in young MS patients and
can lead to ligament injury, dislocations, chronic joint pain
and degenerative arthritis [34]. The facial features of Mar-
fan syndrome include a long and narrow face with deeply
set eyes (enophthalmos), downward slanting of the eyes,
flat cheek bones (malar hypoplasia) and high arched palate
[35]. Ectopia lentis (i.e., lens dislocation) is a cardinal fea-
ture of Marfan syndrome and an ophthalmologic examin-
ation is mandatory in suspected cases. During early
childhood, patients may occasionally present with isolated
bilateral ectopia lentis [36]. The cardiovascular involvement
is particularly worrisome because the progressive aortic-
root dilatation can lead to acute dissection, aneyrysms and
sudden death. Although early diagnosis and refined med-
ical and surgical treatment have improved survival, pa-
tients with Marfan syndrome continue to have high rates
of cardiovascular disease and premature death [37].
The diagnosis is clinical, according to the revised
Ghent criteria (Tables 4 and 5). These criteria however
perform well in patients showing the typical phenotypes.
These criteria are not as useful in milder MS variants,
when only isolated features are present [38]. In young
children Marfan syndrome is not always recognizable,
especially in the absence of a family history, because
many of the more specific clinical features are age
dependent (e.g., ectopia lentis, aortic dilation, dural ectasia,
protrusio acetabuli). A high index of suspicion is needed,
and for subjects suspected to have Marfan syndrome based
on clinical grounds FBN1 testing should be consid-
ered. A useful tool for risk stratification of suspected
pediatric patients can be represented by the Kid-Short
Marfan Score (Table 6) [39].
Diagnosis and management require a multidisciplinary
approach by geneticists, cardiologists, orthopedic surgeons
and ophthalmologists with experience in this field. Cardio-
vascular follow-up should include serial evaluation with
electrocardiography and serial cardiac imaging, especially
CT/MRI angiography. Exercise restriction is wise and
elective aortic-root replacement is sometimes needed [40].
Infective endocarditis prophylaxis is indicated in those
with valvular defects. Medical therapy with beta-blockers
seems to be able to decrease aortic root enlargement, es-
pecially when started relatively early in the disease course,
while the role of ACE inhibitors is still debated [41].
Readers are referred to marfan.org, an excellent resource
for both physicians and patients
Loeys-Dietz syndrome (LDS)
LDS is a recently described rare autosomal dominant
connective tissue disorder characterized by a severe and
Table 4 The revised Ghent criteria for Marfan syndrome
(adapted from Faivre L et al. [38])
In the absence of family history:
1. Aortic Root Dilatation Z score ≥ 2 AND Ectopia Lentis = Marfan
syndrome.
2. Aortic Root Dilatation Z score ≥ 2 AND FBN1 mutations = Marfan
syndrome.
3. Aortic Root Dilatation Z score ≥ 2 AND Systemic Score ≥ 7pts =
Marfan syndrome.
4. Ectopia lentis AND FBN1 with known Aortic Root Dilatation =
Marfan syndrome.
In the presence of family history:
1. Ectopia lentis AND Family History of Marfan syndrome (as defined
above) = Marfan syndrome.
2. A systemic score ≥ 7 points AND Family History of Marfan
syndrome (as defined above) = Marfan syndrome
3. Aortic Root Dilatation Z score ≥ 2 above 20 yrs. old, ≥ 3 below
20 yrs. old) + Family History of Marfan syndrome (as defined
above) = Marfan syndrome.
Table 5 Revised Ghent criteria: systemic feature score (adapted
from Faivre L et al. [38])
Table 2: Revised Ghent Criteria: Systemic features score
• Wrist AND thumb sign – 3 (Wrist OR thumb sign – 1)
• Pectus carinatum deformity – 2 (pectus excavatum or chest
asymmetry – 1)
• Hindfoot deformity – 2 (plain pes planus – 1)
• Pneumothorax – 2
• Dural ectasia – 2
• Protrusio acetabuli – 2
• Reduced US/LS AND increased arm/height AND no severe scoliosis – 1
• Scoliosis or thoracolumbar kyphosis– 1
• Reduced elbow extension – 1
• Facial features (3/5) – 1 (dolichocephaly, enophtalmos, downslanting
palpebral fissures, malar hyoplasia, retrognathia)
• Skin striae – 1
• Mitral valve prolapse (all types) – 1
• Myopia >3 diopters – 1
Maximum total: 20 points; score ≥7 indicates systemic involvement
Bold numbers refer to the points to be scored for each finding
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widespread arterial involvement since childhood. Its
exact incidence have not been established [42, 43]. The
disorder is most often caused by heterozygous mutations
in TGF-β receptors TGFBR1 and TGFBR2 [44]. The
classification depends on the presence or absence of cra-
niofacial features (hypertelorism, bifid uvula and cleft
palate). Affected individuals show generalized arterial
abnormalities, ascending aneurysms and rapidly progres-
sive aortic aneurysm [45]. Skeletal features in all types of
LDS may show overlap with Marfan syndrome (i.e., pec-
tus deformity, arachnodactyly, scoliosis, and pes planus)
but height and proportions are typically within the nor-
mal range. Joint hypermobility is also common. A more
specific finding is the association of arachnodactyly with
advanced carpal bone ossification and joint hyperexten-
sion [46, 47]. LDS diagnostic criteria have not been de-
fined and confirmatory genetic testing is required.
Management of LDS involves regular cardiology follow-
up to establish the extent of vascular involvement, early
surgical intervention, genetic counseling and monitoring
in pregnancy. There is a higher risk of dissection com-
pared to Marfan syndrome, and early surgical correction
may be crucial. Aggressive medication regimens, with β-
blockers and angiotensin receptor antagonists, is recom-
mended as this treatment may halt disease progression
and postpone surgical repair [48].
Stickler syndrome (SS)
SS is a multisystem connective tissue disorder that can
affect the eye, craniofacies, inner ear, skeleton, and joints
[49]. Stickler syndrome has been associated with muta-
tions of COL2A1, which encodes for the alpha-1 chain of
type II collagen, COL11A1 gene, which encodes for the
alpha-1 chain of type XI collagen, and COLL11A2 gene.
Rarer autosomal recessive forms have been linked to mu-
tation of the three genes encoding collagen IX: COL9A1-
2-3. Variable phenotypic expression of Stickler syndrome
occurs both within and among families [50–53].
Based on the vitreous abnormalities Stickler syn-
drome is classified as Type 1 (“membranous”; charac-
terized by a persistence of vestigial vitreous gel in the
retrolental space) and the rare Type 2 (“beaded”, char-
acterized by sparse and irregularly thickened bundles
throughout the vitreous cavity). A non-progressive my-
opia is common. Craniofacial findings may include a
flat facial profile, telecanthus and epicanthal folds,
micrognathia and cleft palate. Hearing impairment, es-
pecially sensorineural deafness for high tones, is com-
mon but the overall sensorineural hearing loss in type I
Stickler syndrome is typically mild and not significantly
progressive. The musculoskeletal features are early-
onset arthropathy, short stature and mild spondyloepi-
physeal dysplasia. In children and adolescents joint hy-
permobility is seen and usually becomes less prominent
with age [52]. The diagnosis of Stickler syndrome is
clinically based. At present, clinical diagnostic criteria
have been proposed only for type 1 Stickler syndrome.
Type 1 individuals have the membranous type of vitre-
ous abnormality (see Table 7). The diagnosis of Stickler
syndrome requires genetic analysis of the involved
genes. The COL2A1 gene may be tested first in individ-
uals with type 1 “membranous” vitreous abnormalities
and milder hearing loss. COL1A1 mutations can be fre-
quently found in patients with craniofacial and joint
manifestations as well as hearing loss but without ocu-
lar findings [53].
Conclusions
Musculoskeletal pain is one of the more common com-
plaints in the pediatric population. It is common for par-
ents of affected children to seek a pediatric evaluation,
and commonly these children are referred to a rheuma-
tologist. Among the leading non-inflammatory causes of
joint pain seen by pediatric rheumatologists are those as-
sociated with hypermobility. Different diseases are associ-
ated with hypermobility. The musculoskeletal complaints
Table 6 The Kids-Short Marfan score (adapted from Mueller GC et al. [39])
Required manifestations Risk category for likelihood of MFS
Dilatation of aortic root + Ectopia lentis Very high risk
• dilatation of aortic root High risk (Complete examination of all symptoms of the revised
Ghent Criteria is strictly recommended as soon as possible.
Patient should see Marfan Syndrome specialists)+ mitral valve prolapse + tricuspid valve prolapse or
+ dilatation of pulmonary artery or
+ at least 3 skeletal features of the systemic score of the revised Ghent criteria
• Ectopia lentis
+ mitral valve prolapse + tricuspid valve prolapse or
+ dilatation of pulmonary artery
Family history dilatation of aortic root Moderate risk (Patient needs to be verified or excluded with
further diagnostic procedures other than or echocardiography
and clinical examination)
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are typical of non-inflammatory conditions, with the onset
of pain that is typically exacerbated by exercise and is usu-
ally a late afternoon/evening pain, without the typical
signs and symptoms of inflammatory arthropathies, such
as joint swelling or morning stiffness. Inflammatory
markers are invariably within normal limits. Many other
clinical manifestations may enrich the clinical picture,
based on the underlying cause. The presence of chronic
pain secondary to hypermobility may have a profound im-
pact on patients’ quality of life, leading to a high burden
for patients, families and the health care system. More-
over, the genetic syndromes depicted in this review may
have early and late severe complications. Pediatricians,
and specifically pediatric rheumatologists, should there-
fore keep a high index of suspicion for early recognition of
hypermobility-associated syndromes. It is essential that
these physicians have expertise in developing an appropri-
ate differential diagnosis in these children and distinguish-
ing one musculoskeletal disease from another.
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